Friedman M A, Marcus F S, Cassidy M J, Resser K J, Kohler M, Hendrickson C G, Reynolds R, Johnson D, Kilbridge T, Yu K, Cruicitt M
Cancer. 1983 Jul 15;52(2):193-7. doi: 10.1002/1097-0142(19830715)52:2<193::aid-cncr2820520202>3.0.co;2-s.
One hundred and thirty-one patients (118 evaluable) with disseminated breast cancer were treated with a combination of 5-fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM). The objective response rate for 82 evaluable patients whose disease was refractory to previous CMF or L-PAM chemotherapy was 35%; that for 36 evaluable patients who had not previously received chemotherapy, 56%. The hematologic toxicity of this therapy was generally mild and acceptable. It is believed that FOAM is an effective therapy for patients whose tumors are resistant to CMF.
131例（118例可评估）播散性乳腺癌患者接受了5-氟尿嘧啶+长春新碱+阿霉素+丝裂霉素C（FOAM）联合治疗。82例可评估患者，其疾病对先前的CMF或左旋苯丙氨酸氮芥化疗耐药，客观缓解率为35%；36例可评估患者，其先前未接受过化疗，客观缓解率为56%。该治疗的血液学毒性一般较轻且可接受。据信，FOAM对肿瘤对CMF耐药的患者是一种有效的治疗方法。
